AbCellera BiologicsABCL
Recorded

AbCellera Biologics 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration33 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Steven WilleySenior Biotech Analyst

All right. Good morning, everyone. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel. Glad to have with us to kick off day two, the CEO of AbCellera, Carl Hansen. Carl, thanks for joining us. Not sure if there's any some opening statements you'd like to make before we jump right into Q&A.

Carl HansenCEO

Thanks for having me, Steve. Yeah, maybe just really quickly, for those that don't know, AbCellera is a biotech company located in Vancouver. We have, over the years, built a platform for the development of antibody medicines. I believe we have a very significant competitive advantage in solving some difficult problems. The mission of the company is to apply that internally and to repeatedly invent, develop, and ultimately commercialize breakthrough medicines. We've made a transition recently, and I think we're going to talk today about ABCL635, which we view as the first evidence of that.

Steven WilleySenior Biotech Analyst

We are going to spend a lot of time on 635.

Steven WilleySenior Biotech Analyst

I figured. if that's okay with you.

Steven WilleySenior Biotech Analyst

All right. You top-lined the data. This is the phase II data back in August.

Steven WilleySenior Biotech Analyst

Yeah. I think it took a lot of us by surprise in a very good way.

Steven WilleySenior Biotech Analyst

Maybe you can just kind of walk us through the high points of the data and how those efficacy and safety metrics compare to the standard of care or small molecules that are on the market.

Carl HansenCEO

Sure. ABCL635 is a first-in-class antibody for the non-hormonal treatment of vasomotor symptoms, or hot flashes, associated with menopause, or that are associated with a menopause-like state that comes from hormone deprivation associated with cancer therapy. It is following a couple small molecules, which you alluded to, fezolinetant and elinzanetant, both of which are approved, one by Astellas and the other by Bayer. We developed an antibody with the hypothesis that an antibody would allow us to dose higher and have better target engagement, and that an antibody would be immune from some of the liabilities of the small molecules, either off-target effects or liver toxicity. We had some preliminary data on that we released earlier, which was a biomarker measurement of testosterone suppression, which showed we could engage the right part of the brain.

Carl HansenCEO

Then the big readout, as you mentioned, was in August, and our TPP was to come up with a product that looked like it had the same efficacy as the small molecules, but was safer and had more convenient dosing once monthly. The upside surprise was that the efficacy turned out to be much, much better. We showed in that data, which was a study of about 92 patients, one-to-one placebo-controlled, that we had a 50% placebo-controlled reduction in hot flashes. That's roughly twice the reduction in frequency that's been seen with either of the small molecules. On the severity score, we had a difference that was anywhere from 3.5 to 5 times as great as the small molecules, and we got all of that with a clean safety profile and a PK/PD relationship that looks like it supports the TPP of once monthly.

Carl HansenCEO

Across the board, we now think we've got a killer product here, and one that could really redefine non-hormonal care for hot flashes, and we are now getting ready to bring that forward into late-stage development.

Steven WilleySenior Biotech Analyst

Okay. Maybe kind of going back to the surprise element of this, right? And I guess from my perspective, there was certainly kind of a suggestion within the small molecule data, right? That there was kind of this ceiling effect on just kind of the magnitude and severity of reduction that you could achieve with this mechanism, and it looks like you were able to break through that ceiling. So, what's your best guess as to what's driving that, right? Because you're leveraging the same mechanism, obviously. Is this a PK/PD receptor occupancy phenomenon?

Carl HansenCEO

Yeah. I think that's right. I think it's a receptor occupancy. It's how completely can you engage and shut down NK3R. And while it's a surprise versus some of the recent data on the small molecules, if you look back at some of the early clinical development of fezolinetant, where they did dose ranging and they looked at efficacy, there certainly is a hint there that they left a lot of efficacy on the table, and that was because of limitations in dosing associated with liver toxicity. So, we had a thesis that you could do better. I think the results even exceeded what our upside scenario was, so we're very pleased with that.

Steven WilleySenior Biotech Analyst

Yeah. Because I think in that fezolinetant dose optimization data that maybe you're referencing, the phase II-A, they pushed dose, what, three times higher?

Steven WilleySenior Biotech Analyst

Yeah. Four times higher Four times higher than the current label dose.

Steven WilleySenior Biotech Analyst

There was a little bit of a reduction, but it certainly wasn't the magnitude of reduction that you guys were able to achieve in the phase II.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day